This meeting took place in 2016


Here are the related meetings in 2017:
Epigenetics and Human Disease: Progress from Mechanisms to Therapeutics (A9)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Enhancer Malfunction in Cancer (Q6)


Organizer(s) Ali Shilatifard and Dale Dorsett
February 21—24, 2016
Santa Fe Community Convention Center • Santa Fe, New Mexico USA
Discounted Abstract Deadline: Oct 20, 2015
Abstract Deadline: Nov 18, 2015
Scholarship Deadline: Oct 20, 2015
Discounted Registration Deadline: Dec 18, 2015

Supported by the Directors' Fund


Summary of Meeting:
Why point mutations in a general transcription factor are associated with specific forms of human malignancies has been a major question in cancer biology. Enhancers are DNA regulatory elements that can be transcribed and are key regulators of tissue-specific gene expression in development; their malfunction through point mutations in either regulatory elements or factors modulating enhancer-promoter communication could result in development problems. Indeed, recent genome-wide studies in the cataloging of somatic mutations in cancer have identified mutations in intergenic sequences encoding regulatory elements and in specific transcription factors that function in enhancer-promoter communication. This Keystone Symposia meeting will review recent reports in this regard and discuss the concept of enhancer malfunction in the misregulation of gene expression in development and in disease pathogenesis.

View Meeting Program

Scholarships/Awards

National Cancer Institute (NCI) Scholarship Recipients

Amin Mahpour
Roswell Park Cancer Institute, USA

Shino Murakami
University of Texas Southwestern Medical Center, USA

Sarah Pyfrom
Washington University in St. Louis, USA